Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0029463 (
osteosarcoma
)
16,637
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The form of selenium appears to be important for preventing cancer in humans. Here, we evaluated selenium levels in the serum and bone tissue samples from
osteosarcoma
patients using atomic absorption spectrometry. The in vitro effects of
Se-methylselenocysteine
(Se-MSC) on growth, cell cycle status, and apoptosis of
osteosarcoma
cells were assessed using the WST-1 assay, Hoechst 33342/propidium iodide staining, and flow cytometry, respectively. In
osteosarcoma
cases, the mean serum selenium levels in
osteosarcoma
tissue and normal bone were 0.08 mg/kg and 0.03 mg/kg, respectively (P < 0.05). Serum selenium levels in
osteosarcoma
and non-
osteosarcoma
cases were 0.09 mg/L and 0.08 mg/L, respectively (P > 0.05). Se-MSC-treated MG63 cells showed altered cellular morphology, decreased viability in a time- and dose-dependent manner, and an increase in the sub-G1 cell population. Se-MSC also downregulated Bcl-2 expression and upregulated Bax. Se-MSC inhibited the proliferation of the drug-resistant
osteosarcoma
cell line Saos-2/MTX300 and enhanced the inhibitory effect of pirarubicin on MG63 cells. Our data demonstrate that selenium levels are significantly higher in
osteosarcoma
tissue than normal bone tissue in
osteosarcoma
patients. The results also support the anticancer effects of Se-MSC in
osteosarcoma
. Further development of Se-MSC as an ancillary chemotherapy agent in
osteosarcoma
is warranted.
...
PMID:Analysis of Selenium Levels in Osteosarcoma Patients and the Effects of Se-Methylselenocysteine on Osteosarcoma Cells In Vitro. 2612 31